Allergan, Ironwood Seek To Divide And Conquer IBS With New Linzess Formulations
Allergan and Ironwood Pharmaceuticals are beefing up the blockbuster potential of their IBS drug Linzess with two new formulations that target different disease populations showing promising Phase II data. Further Phase IIb and III trials are now in the offing.
You may also be interested in...
Citing concerns that Linzess might not hit the blockbuster threshold by 2020, as predicted by Ironwood, one analyst lowers the firm’s stock rating on the same day the company clarifies that it does not want activist investor Alex Denner to join its board.
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.